Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris
作者： R. Gniadecki , B. Bang , L.E. Bryld , L. Iversen , S. Lasthein
DOI: 10.1111/BJD.13343
关键词:
摘要: SummaryBackground Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long-term therapeutic performance in a real-life setting. Biologic psoriasis is mainly limited by gradual loss of efficacy over time. Previous studies have been small patient population size and short observation times yielded discrepant for different biologics. Objectives To calculate adalimumab, etanercept, infliximab ustekinumab large cohort patients with vulgaris analyse factors that influence survival. Patients methods Data were extracted from prospective registry DERMBIO covering all treated biologic agents academic centres Denmark. Drug was analysed using Kaplan–Meier method. The covariates on Cox regression. Results Included analysis 1867 treatment series (adalimumab n = 774, etanercept n = 449, n = 253, n = 391) administered 1277 up 10 years. significantly longer than anti-tumour necrosis factor (TNF)-α (P < 0·001). Etanercept had shortest time [median 30 months, 95% confidence interval (CI) 25·1–34·9] whereas adalimumab comparable rates (59 months, CI 45·6–72·4; 44 months, 33–54·9, respectively). Survival men [odds ratio (OR) 1·51, 1·31–1·74 vs. women] who not previously received any agent (OR 1·24, 1·05–1·46). Loss accounted 67% discontinuations. Conclusions Ustekinumab anti-TNF-α agents. Switching one another associated impairment survival. Preventing major area medical need therapy strategies improve should be further investigated.
sci-hub.se 参考文章(22)
A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li, K.A. Papp, Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. British Journal of Dermatology. ,vol. 166, pp. 861- 872 ,(2012) , 10.1111/J.1365-2133.2012.10901.X
K. Reich, A.D. Burden, J.N. Eaton, N.S. Hawkins, Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. British Journal of Dermatology. ,vol. 166, pp. 179- 188 ,(2012) , 10.1111/J.1365-2133.2011.10583.X
Kim A. Papp, Yves Poulin, Robert Bissonnette, Marc Bourcier, Darryl Toth, Leslie Rosoph, Melanie Poulin-Costello, Mike Setterfield, Jerry Syrotuik, Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population Journal of The American Academy of Dermatology. ,vol. 66, ,(2012) , 10.1016/J.JAAD.2010.07.026
A. López-Ferrer, E. Vilarrasa, I.J. Gich, L. Puig, Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. British Journal of Dermatology. ,vol. 169, pp. 1141- 1147 ,(2013) , 10.1111/BJD.12543
M. Esposito, P. Gisondi, N. Cassano, G. Ferrucci, M. Del Giglio, F. Loconsole, A. Giunta, G.A. Vena, S. Chimenti, G. Girolomoni, Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study British Journal of Dermatology. ,vol. 169, pp. 666- 672 ,(2013) , 10.1111/BJD.12422
J.M.P.A. Reek, P.P.M. Lümig, R.J.B. Driessen, P.C.M. Kerkhof, M.M.B. Seyger, W. Kievit, E.M.G.J. Jong, Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis British Journal of Dermatology. ,vol. 170, pp. 415- 424 ,(2014) , 10.1111/BJD.12648
M. Papoutsaki, M. Talamonti, A. Giunta, A. Costanzo, M. Ruzzetti, M. Teoli, S. Chimenti, The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. ,vol. 221, pp. 43- 47 ,(2010) , 10.1159/000316184
P.L. Mattei, K.C. Corey, A.B. Kimball, Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies Journal of The European Academy of Dermatology and Venereology. ,vol. 28, pp. 333- 337 ,(2014) , 10.1111/JDV.12106
K. Reich, L. Puig, C. Paul, K. Kragballe, T. Luger, J. Lambert, S. Chimenti, G. Girolomoni, J.‐F. Nicolas, E. Rizova, M. Brunori, S. Mistry, P. Bergmans, J. Barker, Z. Adamski, G. Altomare, M. Aricò, N. Aste, F. Aubin, M. Augustin, F. Ayala, H. Bachelez, E. Baran, J. Barker, I. Belinchón, P. Berbis, M.G. Bernengo, D. Bessis, M. Beylot‐Barry, F.J. Bordas Orpinell, D. Burden, M. Bylaite, F. Cambazard, S. Carazo, J.M. Carrascosa, G. Carretero, R. Cerio, S. Chimenti, M. David, A.B. Duval‐Modeste, D. Eedy, L. Estebaranz, P. Filipe, I. Flytström, E. Fonseca, R. Gamanya, P.‐D. Ghislain, A. Giannetti, G. Girolomoni, D. Gospodinov, C. Griffiths, J.‐J. Grob, G. Guillet, J.M. Hernanz Hermosa, M. Hoffmann, D. Ioannidis, A. Jacobi, G. Jemec, M. Kadurina, K. Kaszuba, A. Katsambas, L. Kemeny, P. Kerkhof, K. Kragballe, N. Kuzmina, K. Lambert, P. Lázaro, T. Lotti, T. Luger, H. Matz, P. Modiano, R. Moessner, D. Moreno, J.C. Moreno Jímenez, N.J. Mørk, U. Mrowietz, R. Murphy, J.‐F. Nicolas, A. Nikkels, H. Oliveira, A. Ormerod, J.‐P. Ortonne, A. Parodi, R. Pasternack, C. Paul, J. Pec, A. Peserico, S. Philipp, L. Piquet, P. Plantin, L. Puig, K. Reich, E. Reményik, E. Riedl, M. Röcken, M. Rustin, S. Saari, P. Saiag, W. Salmhofer, D. Schadendorf, M. Sebastian, M. Simaljakova, J.C. Simon, A. Spirén, J.‐F. Stalder, N. Stavrianeas, M. Sticherling, T. Ternowitz, D. Thaci, B. Thio, D. Uhlig, S. Valiukeviciene, F.J. Vanaclocha Sebastián, G. Wozel, , One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis British Journal of Dermatology. ,vol. 170, pp. 435- 444 ,(2014) , 10.1111/BJD.12643
Kenneth Gordon, Kim Papp, Yves Poulin, Yihua Gu, Stephen Rozzo, Eric H. Sasso, Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. Journal of The American Academy of Dermatology. ,vol. 66, pp. 241- 251 ,(2012) , 10.1016/J.JAAD.2010.12.005